Salem Investment Counselors Inc. Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)

Salem Investment Counselors Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,926 shares of the company’s stock after acquiring an additional 491 shares during the quarter. Salem Investment Counselors Inc.’s holdings in Novo Nordisk A/S were worth $1,886,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC raised its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its holdings in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S during the third quarter worth about $98,765,000. Marshall Wace LLP lifted its holdings in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $84.43 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market capitalization of $378.88 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a 50 day moving average price of $99.84 and a 200 day moving average price of $118.61. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.